摘要:
The invention relates autonomous VH domains (aVH) with cysteines in positions 52a and 71 or in positions 33 and 52 in order to stabilize the autonomous VH domains. Said cysteines are capable of forming a disulfide bond and/or form a disulfide bond under suitable conditions. 5 The invention further relates to aVH libraries.
摘要:
The present invention relates to a bispecific antibody comprising a first binding domain capable of binding to a first target and a second binding domain capable of binding to a second target, wherein (i) said second binding domain comprises a V H and a V L domain capable of binding a second target and wherein (ii) said first binding domain comprises a single chain F v region capable of binding a first target, which is coupled to the constant domain of the light chain of said second binding domain.
摘要:
Provided is an erythropoietin-producing hepatocellular carcinoma receptor (EphR)-binding agent comprising: a first binding agent which specifically binds a first EphR and a second binding agent which binds a second EphR, optionally EphA2 and EphA3. Also provided are uses of the EphR-binding agent for treating or preventing glioblastoma multiforme (GBM).
摘要:
The present invention provides multivalent and multispecific binding proteins that are capable of binding two or more antigens, or two or more epitopes. The present invention also provides methods of making and using such multivalent and multispecific binding proteins, including methods of using such binding proteins for prevention or treatment of various diseases, or for detecting specific antigens in vitro or in vivo.
摘要:
The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to PSMA, a second domain binding to an extracellular epitope of the human and the Macaca CD3 E chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
摘要:
The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to BCMA, a second domain binding to an extracellular epitope of the human and/or the Macaca CD3ε chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
摘要:
The present invention pertains to the provision of bi-specific anti-EGFR x c-MET strand- exchange engineered domain C H 3 heterodimer antibodies (SEED-bodies), methods of producing the same. Disclosed are also antibody-drug conjugates comprising the anti-EGFR x c-MET heterodimeric bispecific immunoglobulin molecules (SEED-bodies) of the invention, methods of manufacturing the same and their use in cancer therapy.
摘要翻译:本发明涉及提供双特异性抗EGFR x c-MET链交换工程化结构域C≡H3异二聚体抗体(SEED-体),方法 生产相同。 还公开了包含本发明的抗EGFR x c-MET异二聚体双特异性免疫球蛋白分子(SEED体)的抗体 - 药物缀合物,其制备方法以及它们在癌症治疗中的用途。 p>
摘要:
The present disclosure relates to a recombinant immunoglobulin heavy chain comprising a VH-domain a CH1 domain a hinge region down to the C-terminal most cysteine of the middle hinge region, a sortase conjugation loop, a CH2 domain and a CH3 domain, wherein the sortase conjugation loop a) consists of at least 16 amino acids located between the C-terminal most cysteine of the middle hinge region and the VFX1FPP (SEQ ID NO: 2; wherein X1 is L or I) consensus sequence at the N-terminus of an immunoglobulin heavy chain CH2-domain, b) comprises a sortase recognition motif consisting of the amino acid sequence LPX1TX2 (SEQ ID NO: 01), wherein X1 can be any amino acid residue and X2 is G or A, c) comprises N-terminal to the sequence of (b) at least two amino acids, d) comprises C-terminal to the sequence of (b) at least 6 amino acids, and e) wherein the amino acids C- and N-terminal to the sequence of (b) are not cysteine and its use in site-directed conjugation based on the enzyme sortase.
摘要翻译:本公开涉及重组免疫球蛋白重链,其包含VH结构域CH1结构域到中间铰链区的C末端最多半胱氨酸的铰链区,分选酶缀合环,CH2结构域和CH3结构域,其中 分选酶缀合环a)由位于中间铰链区的C末端最多半胱氨酸和VFX1FPP(SEQ ID NO:2;其中X1是L或I)的至少16个氨基酸组成,其中N是N末端的共有序列 免疫球蛋白重链CH2结构域,b)包含由氨基酸序列LPX1TX2(SEQ ID NO:01)组成的分选酶识别基序,其中X1可以是任何氨基酸残基,X2是G或A,c)包括N- (b)至少两个氨基酸的序列的末端,d)包含(b)至少6个氨基酸的序列的C末端,以及e)其中所述序列的氨基酸C和N-末端 (b)不是半胱氨酸,并且其用于基于酶分选酶的定点共轭。
摘要:
This disclosure generally provides molecules that specifically engage glucocorticoid-induced TNFR-related protein (GITR), a member of the TNF receptor superfamily (TNFRSF). More specifically, the disclosure relates to multivalent and/or multispecific molecules that bind at least GITR.